探讨依达拉奉在临床上治疗急性脑梗死的有效性和安全性。

选择延边大学附属医院神经内科自2018年1月至2019年1月符合标准的急性脑梗死患者120例，简单随机化分组为观察组和对照组，每组60例，2组患者均使用常规急性脑梗死治疗方法，观察组在常规治疗的基础上，加用依达拉奉注射液；在治疗后14、21 d对2组患者行临床疗效判定，判定指标包括日常生活活动能力量表（ADL）以及美国国立卫生研究院脑卒中量表（NIHSS），同时比较2组患者不良反应情况。

观察组治疗有效率为88.33%，对照组治疗有效率为73.33%，2组患者比较差异有统计学意义（P<0.05）；观察组在ADL评分及NIHSS评分改善幅度上均优于对照组，差异有统计学意义（P<0.05）；2组患者在治疗期间均未出现严重不良反应。

依达拉奉在治疗急性脑梗死过程中可以改善神经功能缺损、提高日常生活活动能力，增强治疗效果且安全可靠，值得临床推广应用。

To investigate the effect and safety of edavarone in the treatment of acute cerebral infarction.

Totally, 120 patients, admitted to Department of Neurology of Yanbian University Hospital from January 2018 to January 2019, were randomly divided into control group (60 cases) and observation group (60 cases). Both groups were given conventional treatment, but the patients in observation group were given edaravone additonally. On 14 and 21 d after treatment, the clinical effect was evaluated using the chart of ADL and NIHSS.

The therapeutic effective rates were 88.33% and 73.33% for observation group and control group, respectively. Meanwhile, significant improvement could be seen by the score of ADL and NIHSS on day 7 and day 14 after treatment in observation group, and there was significant difference between these two groups. More, no severe drug associated side-effect were observed in each group.

Edavarone can improve neurological deficits as well ADL score in acute cerebral infarction patients, resulting in good therapeutic efficacy, and it is worth of application as a safe drug.